Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: Results from the VARA registry

Department of Medicine, Omaha Veterans Affairs Medical Center (VAMC), University of Nebraska, Omaha, NE 68198-6270, USA.
Rheumatology (Oxford, England) (Impact Factor: 4.48). 01/2011; 50(1):101-9. DOI: 10.1093/rheumatology/keq232
Source: PubMed


To examine the all-cause mortality rate and factors associated with mortality in US veteran men with RA.
Men with RA were enrolled and followed until death or censoring. Vital status was ascertained through systematic record review and standardized mortality ratios (SMRs) were calculated using US life tables for men. Multivariate Cox proportional hazards regression was used to examine the independent associations of patient factors including socio-demographics, comorbidity, measures of RA disease activity/severity and medication use with mortality. Measures of RA disease activity and medications were examined as time-varying factors.
A total of 138 deaths were observed during 2314 patient-years of follow-up (n=1015 patients), corresponding to a crude morality rate of 5.9 deaths per 100 patient-years (95% CI 5.0, 7.0) and an SMR of 2.1 (95% CI 1.8, 2.5). After multivariate adjustment, factors independently associated with higher mortality risk in men with RA included older age, Caucasian race, low body weight, an increased frequency of rheumatology visits, higher ESR and RF concentrations, increased DAS28, subcutaneous nodules and prednisone use. In contrast, MTX use [hazard ratio (HR) 0.63; 95% CI 0.42, 0.96] was associated with ∼40% lower mortality risk.
Mortality rates among US male veterans with RA are more than twice those of age-matched men in the general population. These results suggest that optimizing disease control, particularly with regimens that include MTX and minimize glucocorticoid exposure, could improve long-term survival in this population.

Download full-text


Available from: Kaleb Michaud,
  • Source
    • "Rheumatoid arthritis (RA), which affects 0.5–1% of the population in the industrialized world (Symmons, 2002), is a systemic autoimmune disease characterized by chronic and progressive inflammation in multiple joints, leading to irreversible tissue damage and deformity that culminates in disability , a lower quality of life and in many cases premature death (Mikuls et al., 2011). It is initially characterized by inflammatory synovitis involving a broad range of cells such as macrophages, neutrophils, B cells, T cells and synovial fibroblasts. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and purpose: For antibody therapies against receptor targets, in vivo outcomes can be difficult to predict because of target-mediated clearance or antigen 'sink' effects. The purpose of this work was to engineer an antibody to the GM-CSF receptor α (GM-CSFRα) with pharmacological properties optimized for chronic, s.c. treatment of rheumatoid arthritis (RA) patients. Experimental approach: We used an in silico model of receptor occupancy to guide the target affinity and a combinatorial phage display approach for affinity maturation. Mechanism of action and internalization assays were performed on the optimized antibody in vitro before refining the modelling predictions of the eventual dosing in man. Finally, in vivo pharmacology studies in cynomolgus monkeys were carried out to inform the predictions and support future clinical development. Key results: Antibody potency was improved 8600-fold, and the target affinity was reached. The refined model predicted pharmacodynamic effects at doses as low as 1 mg kg(-1) and a study in cynomolgus monkeys confirmed in vivo efficacy at 1 mg kg(-1) dosing. Conclusions and implications: This rational approach to antibody drug discovery enabled the isolation of a potent molecule compatible with chronic, s.c. self-administration by RA patients. We believe this general approach enables the development of optimal biopharmaceuticals.
    British Journal of Pharmacology 08/2012; 168(1). DOI:10.1111/j.1476-5381.2012.02173.x · 4.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ziel ist eine Risiko-Nutzen-Bewertung der Therapie der rheumatoiden Arthritis mit Biologika anhand der durch die Register publizierten Daten zur Mortalität.Aus drei Registern (Großbritannien, Schweden und Spanien) liegen auswertbare Daten zur Mortalität vor. In Großbritannien gibt es eine parallele Kontrollgruppe, in Schweden und Spanien wurde eine historische Kohorte zum Vergleich gewählt.Die britische und schwedische Untersuchung können sich auf eine automatische Meldung aus Sterberegistern stützen. Die Vielzahl möglicher Störgrößen verhindert Vergleiche der Register, aber auch pauschale und sichere Vorhersagen für individuelle Patienten.Die Sterberate unter TNF-Inhibition ist höher als in der Allgemeinbevölkerung, aber niedriger als in den Kontrollgruppen. Werden die Untersuchungen bezüglich möglicher Störgrößen wie Komorbiditäten gewichtet, nimmt der Unterschied zwischen exponierten Patienten und Kontrollen ab. Werden TNF-Inhibitoren in üblicher Indikation gegeben, ist die Mortalität im Vergleich zur konventionellen Therapie in Abhängigkeit von der Kontrollgruppe leicht bis deutlich vermindert.
    Zeitschrift für Rheumatologie 01/2010; 69(9). DOI:10.1007/s00393-010-0641-1 · 0.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Veterans Affairs (VA) Rheumatoid Arthritis (VARA) registry and the VA Pharmacy Benefits Management database were linked to determine the association of methotrexate (MTX) adherence with rheumatoid arthritis (RA) disease activity. For each patient, the medication possession ratio (MPR) was calculated for the first episode of MTX exposure of a duration of ≥12 weeks for both new and established MTX users. High MTX adherence was defined as an MPR ≥0.80 and low MTX adherence was defined as an MPR <0.80. For each patient, the mean Disease Activity Score with 28 joints (DAS28) score, erythrocyte sedimentation rate (ESR), and C-reaction protein (CRP) level observed during registry followup were compared in high- versus low-adherence groups. In 455 RA patients, the prescribed doses of MTX (mean ± SD 16 ± 4 mg versus 16 ± 4 mg; P = 0.6) were similar in high-adherence patients (n = 370) in comparison to low-adherence patients (n = 85). However, the actual observed MTX doses taken by patients were significantly higher in the high-adherence group (mean ± SD 16 ± 5 mg versus 11 ± 3 mg; P < 0.001). DAS28 (mean ± SD 3.6 ± 1.2 versus 3.9 ± 1.5; P < 0.02), ESR (mean ± SD 24 ± 18 versus 29 ± 24 mm/hour; P = 0.05), and CRP level (mean ± SD 1.2 ± 1.3 versus 1.6 ± 1.5 mg/dl; P < 0.03) were lower in the high-adherence group compared to those with low MTX adherence. These variances were not explained by differences in baseline demographic features, concurrent treatments, or whether MTX was initiated before or after VARA enrollment. High MTX adherence was associated with improved clinical outcomes in RA patients treated with MTX. Adjustment for potential confounders did not alter the estimated effect of adherence. These results demonstrate the advantages of being able to merge clinical observations with pharmacy databases to evaluate antirheumatic drugs in clinical practice.
    12/2011; 63(12):1680-90. DOI:10.1002/acr.20629
Show more